Medpace (NASDAQ:MEDP) Stock: Insider August Troendle Sells 27,833 Shares

Key Points

• CEO August Troendle sold 27,833 Medpace shares at an average price of $621.33, generating approximately $17.3 million; his direct ownership fell 6.67% to 389,456 shares.
• Medpace shares traded down 0.3% to $618.88, while the company reported quarterly EPS of $4.25 and revenue of $707.33 million, both above analyst expectations. Revenue increased 17.2% year over year.
• Analysts maintain a consensus “Hold” rating with an average price target of $595.20, and institutional investors own approximately 77.98% of Medpace’s outstanding stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 27,833 shares of the business's stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $621.33, for a total transaction of $17,293,477.89. Following the sale, the chief executive officer directly owned 389,456 shares of the company's stock, valued at $241,980,696.48. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Medpace Trading Down 0.3%

Shares of MEDP traded down $1.71 during midday trading on Friday, reaching $618.88. 229,012 shares of the company were exchanged, compared to its average volume of 332,429. The company has a market cap of $17.27 billion, a price-to-earnings ratio of 36.28, a P/E/G ratio of 2.81 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The stock has a 50-day moving average price of $593.03 and a 200-day moving average price of $515.26.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. The firm's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on MEDP shares. Mizuho boosted their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. TD Cowen increased their price target on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group reaffirmed a "hold" rating on shares of Medpace in a research note on Monday, September 14th. Finally, Robert W. Baird increased their target price on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $595.20.

Institutional Investors Weigh In On Medpace

A number of hedge funds have recently bought and sold shares of MEDP. Schulhoff & Co. Inc. boosted its stake in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock worth $1,237,000 after acquiring an additional 25 shares in the last quarter. Balefire LLC increased its position in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after buying an additional 26 shares in the last quarter. Root Financial Partners LLC increased its position in shares of Medpace by 34.1% in the first quarter. Root Financial Partners LLC now owns 122 shares of the company's stock valued at $59,000 after buying an additional 31 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Medpace by 2.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock worth $613,000 after buying an additional 32 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in Medpace by 0.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company's stock worth $3,718,000 after acquiring an additional 40 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.